Cell and Gene Outsourcing

  1. Get To Know: Oligonucleotide Synthesis Workflow 2/12/2026

    Discover the basics of synthetic oligonucleotides, from their building blocks to stepwise synthesis and purification.

  2. January 2026 — CDMO Opportunities And Threats Report 2/12/2026

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  3. Smart Scaling For Cell And Gene Therapies 2/5/2026

    To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.

  4. AI And Digital Maturity In Contract Development And Manufacturing 2/5/2026

    Explore how CDMOs are navigating digital maturity, where AI is driving real operational gains, and why sponsor expectations are accelerating the push toward digital readiness.

  5. Why Compliance-Driven CDMOs Win Sponsor Contracts 2/5/2026

    Learn how digital maturity and compliance excellence are reshaping CDMO competitiveness, as well as strategies that strengthen performance and accelerate tech transfers.

  6. Accelerate LNP Manufacturing With Automated Process Development 2/5/2026

    Manual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.

  7. Derisk Multimodal CGT Manufacturing With These Key CDMO Capabilities 2/4/2026

    For CGT sponsors developing multiple modalities, choosing one CDMO partner that can manufacture each of their drugs enables speed and consistency. However, developers must be rigorous in their assessment of multimodal partners, evaluating contamination control, technical prowess, quality infrastructure, and regulatory expertise.

  8. Proven Expertise And Customized End-To-End Solutions For Your Products 2/3/2026

    Accelerate biological breakthroughs with integrated services spanning process development, large-scale drug substance manufacturing, and high-speed aseptic fill/finish.

  9. Engineering Reliability In Cell Therapy Manufacturing 2/3/2026

    A cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.

  10. Compressing Tech Transfer Timelines Through Digital CMC Standardization 2/2/2026

    Digital CMC platforms address tech transfer inefficiencies by unifying process knowledge, reducing compliance risk, and significantly compressing CDMO onboarding timelines.